Big Moving Stock keep track of the biggest moving stocks in the market.


Nasdaq: GOOG NFLX AMZN IBB TSLA WYNN AMGN Z COST SSYS SBAC GILD VRTX MDVN AAPL SNDK WDC TRIP MNST
Nyse: ACT V LNKD IVV PXD IBM GS LMT AGN SPG FDX TWC PRGO MMM CMI HUM APD BA GD XEC
New Highs: CF SLXP PII UTHR DRC GPRO PRXL CCL

The Hot Industries

Medical Laboratories & Research 1
Resorts & Casinos 1
Diversified Machinery 1

The Hot Sectors

Healthcare 3
Services 1
Industrial Goods 1

AMRN Stock Chart


AMRN
Analyze

Sector:

Healthcare
Daily

Industry:

Drug Manufacturers - Other
Weekly

Employees:

185
Monthly

Website:

http://www.amarincorp.com

AMRN Amarin Corporation plc

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases in the United States. It develops products in the areas of lipid science and therapeutic benefits of polyunsaturated fatty acids. The company markets Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It is also developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.

favicon

InPlay from Briefing.com

23 Sep 2014, 9:56 amInPlay from Briefing.com
favicon

Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma

22 Sep 2014, 6:56 amLONDON, September 22, 2014 /PRNewswire/ -- The US markets on Friday, September 19, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,279.74, up 0.08% and the NASDAQ Composite closed at 4,579.79, down 0.30%. The S&P 500 finished the session 0.05% lower at...
favicon

Biotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved - Analyst Blog

17 Sep 2014, 2:13 pmBiotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved - Analyst Blog
favicon

Biotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved

17 Sep 2014, 12:00 pmFDA approvals, a positive FDA panel outcome and positive phase II data were the key highlights in the biotech sector last week.
favicon

Amarin Plunges after the FDA Denies Vascepa SPA Appeal - Analyst Blog

15 Sep 2014, 4:07 pmAmarin Plunges after the FDA Denies Vascepa SPA Appeal - Analyst Blog
favicon

Amarin Plunges after the FDA Denies Vascepa SPA Appeal

15 Sep 2014, 1:45 pmAmarin Corporation (AMRN) announced that the FDA's Office of New Drugs denied the company's appeal regarding the rescission of the Special Protocol Assessment covering the phase III ANCHOR study on Vascepa....
favicon

Week Concludes With S&P 500 Below 2,000; Dow Below 17,000

12 Sep 2014, 2:51 pmThe S&P 500 finished the week below 2,000 points while the Dow was unable to hold 17,000 points. Volume was notably higher during Friday's session following weeks of light trading activity. Major Averages ...
favicon

Conversant Shares Rise On Acquisition News; Health Care REIT Drops

12 Sep 2014, 12:02 pmMidway through trading Friday, the Dow traded down 0.41 percent to 16,979.45 while the NASDAQ declined 0.45 percent to 4,571.27. The S&P also fell, dropping 0.54 percent to 1,986.63. Leading and Lagging ...
favicon

Why Amarin (AMRN) Stock Is Plummeting Today

12 Sep 2014, 9:59 amNEW YORK (TheStreet) -- Shares ofaAmarina plunged 23.76% to $1.38 Friday after the company announced that the FDA denied its appeal to reinstate Special Protocol Assessment status on a phase IIIastudy of the company'saprescription fish-oil pill Vascepa. John Jenkins, the headaofficial in the FDA's Office of New Drugs, denied the appeal. This is the third time Amarin has been rejected when ...
favicon

Is Amarin Corporation (AMRN) Stock a Solid Choice Right Now?

3 Sep 2014, 4:45 amAmarin Corporation has seen a nice streak of beating earnings estimates at the previous two reports, suggesting it has a nice short-term history of crushing expectations and that it could be a great candidate ...